share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  04/16 16:12
Moomoo AI 已提取核心信息
bluebird bio, Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission, which granted a 15-day extension until April 16, 2024, for the filing. However, due to the time required to complete the necessary procedures for restating its consolidated financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of both 2023 and 2022, bluebird bio will not meet the extended deadline. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements. The company is working to finalize the 2023 Form 10-K as soon as possible and anticipates a delay in filing its Quarterly Report on Form 10-Q for the first quarter of 2024 as well. bluebird bio has stated that the restatements are not expected to affect its cash position or revenue.
bluebird bio, Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission, which granted a 15-day extension until April 16, 2024, for the filing. However, due to the time required to complete the necessary procedures for restating its consolidated financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of both 2023 and 2022, bluebird bio will not meet the extended deadline. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements. The company is working to finalize the 2023 Form 10-K as soon as possible and anticipates a delay in filing its Quarterly Report on Form 10-Q for the first quarter of 2024 as well. bluebird bio has stated that the restatements are not expected to affect its cash position or revenue.
蓝鸟生物公司宣布延迟提交截至2023年12月31日财年的10-K表年度报告。该公司此前曾向美国证券交易委员会提交了12b-25表格,该委员会批准将申报期限延长15天,至2024年4月16日。但是,由于完成重报截至2022年12月31日止年度的合并财务报表的必要程序以及2023年和2022年前三个季度的未经审计的财务信息需要时间,蓝鸟生物将无法在延长的截止日期之前完成。重报与确定嵌入式租赁和对租赁协议中非租赁部分的处理有关。该公司正在努力尽快完成2023年10-K表格,并预计延迟提交2024年第一季度的10-Q表季度报告。蓝鸟生物表示,重报预计不会影响其现金状况或收入。
蓝鸟生物公司宣布延迟提交截至2023年12月31日财年的10-K表年度报告。该公司此前曾向美国证券交易委员会提交了12b-25表格,该委员会批准将申报期限延长15天,至2024年4月16日。但是,由于完成重报截至2022年12月31日止年度的合并财务报表的必要程序以及2023年和2022年前三个季度的未经审计的财务信息需要时间,蓝鸟生物将无法在延长的截止日期之前完成。重报与确定嵌入式租赁和对租赁协议中非租赁部分的处理有关。该公司正在努力尽快完成2023年10-K表格,并预计延迟提交2024年第一季度的10-Q表季度报告。蓝鸟生物表示,重报预计不会影响其现金状况或收入。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息